USV (CENTRA) - search results

United States - English - NLM (National Library of Medicine)

susvimo- ranibizumab injection, solution

genentech, inc. - ranibizumab (unii: zl1r02vt79) (ranibizumab - unii:zl1r02vt79) - susvimo (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (amd) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (vegf) inhibitor medication. susvimo (ranibizumab injection) is contraindicated in patients with ocular or periocular infections. susvimo (ranibizumab injection) is contraindicated in patients with active intraocular inflammation. susvimo (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in susvimo (ranibizumab injection). risk summary there are no adequate and well-controlled studies of susvimo (ranibizumab injection) administration in pregnant women. administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure (based on serum levels following the re